[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 426
Citations 0
Clinical Trials Update
October 27, 2015

PrEP Reduces Incidence of HIV in Clinical Settings

JAMA. 2015;314(16):1684. doi:10.1001/jama.2015.13424

Daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection among gay men at high risk of becoming HIV positive, according to an open-label randomized trial designed to assess the real-life effectiveness of PrEP. Concerns had been raised that individuals taking PrEP would engage in riskier sexual practices, counteracting the benefits of PrEP. However, the investigators suggest these findings provide evidence that the effectiveness of PrEP would not be compromised by behavioral “risk compensation” (McCormack S et al. Lancet. doi:10.1016/S0140-6736(15)00056-2 [published online September 9, 2015]).

First Page Preview View Large
First page PDF preview
First page PDF preview
×